BIOLASE Inc
Change company Symbol lookup
Select an option...
BIOL BIOLASE Inc
GOEV Canoo Inc
CHE Chemed Corp
ASTA WorldFlix Inc
$NQDM15LMCADN Nasdaq Developed Markets Telecommuni
BFZ BlackRock California Municipal Income Trust
CAR Avis Budget Group Inc
GIS General Mills Inc
VLN Valens Semiconductor Ltd
CIF MFS? Intermediate High Income Fund
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Health Care Equipment & Supplies | Small Cap Blend
Company profile

BIOLASE, Inc. (BIOLASE) provides laser systems for the dental industry. The Company develops, manufactures, markets and sells laser systems for dental practitioners and their patients. It offers two categories of laser system products: Waterlase (all-tissue) systems and diode (soft-tissue) systems. Waterlase dental laser systems flagship consist of the Waterlase Express, Waterlase iPlus, and the Waterlase MD and MDX which, produces electromagnetic energy with specific absorption and tissue interaction characteristics specifically designed for dental procedures in cutting hard tissue, such as bone and teeth, and soft tissue, such as gums and skin, without the heat, vibration, bleeding, or pressure associated with traditional dental treatments. Its diode soft tissue laser systems consist of the Epic X, Epic Hygiene, Epic Pro, Epic 10 and iLase diode lasers that perform soft tissue, hygiene, cosmetic procedures, teeth whitening, and provide temporary pain relief.

Closing Price
$0.5905
Day's Change
-0.0201 (-3.29%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.612
Day's Low
0.5895
Volume
(Heavy Day)
Volume:
2,583,855

10-day average volume:
1,378,322
2,583,855

Moderna Announces the Launch of Global Fellowship Program for Young Researchers Exploring mRNA Medicines

8:30 am ET October 6, 2021 (BusinessWire) Print

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the launch of the Moderna Fellowship Program. The goal of the program is to support the next generation of scientists and healthcare professionals as they innovate in the field of mRNA research towards improving patient care and population health.

Prospective fellows may be clinicians and scientists who are interested in advancing mRNA research and innovation and the program underpins Moderna's commitment to supporting independent research. The fellowship program will select approximately 50 global fellows in the first year with a focus on infectious diseases. Greg Poland, M.D., infections disease expert and Director of Mayo Clinic's Vaccine Research Group, will serve as Chair of the program.

"We're at a critical moment for mRNA vaccine development," said Dr. Poland. "The time is now for investing in talent and idea generation that will propel a new era for research of mRNA approaches to infectious disease - and eventually, other therapeutic areas."

"At Moderna, we aspire to make a positive impact today and in the decades to come. We are humbled by the opportunity to help a new network of collaborators around the world advance mRNA research," said Stephane Bancel, Chief Executive Officer of Moderna. "This program presents an opportunity for us to build and scale a new generation of mRNA scientists, researchers and healthcare professionals to improve quality of care by educating and advocating for clinical best practices with mRNA vaccines and therapeutics."

The fellowship program will be overseen by an independent steering committee of international experts in science, medicine, and healthcare. The committee expects to receive applications from institutions around the world who wish to appoint a fellow in either clinical medicine, scientific research or another healthcare related discipline. To learn more, please visit www.modernatx.com/research-fellowship.

About Moderna

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use of one of the earliest and most effective vaccines against the COVID-19 pandemic.

Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past six years. To learn more, visit www.modernatx.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the Company's launch of a global fellowship program for researchers exploring mRNA medicines and the design and potential impact of that program. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include those other risks and uncertainties described under the heading "Risk Factors" in Moderna's most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date hereof.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211006005341/en/

SOURCE: Moderna, Inc.

Media 
Colleen Hussey
Director, Corporate Communications
(617) 335-1374
Colleen.Hussey@modernatx.com 

Investors 
Lavina Talukdar
Senior Vice President & Head of Investor Relations
(617) 209-5834
Lavina.Talukdar@modernatx.com
comtex tracking

COMTEX_394664225/1006/2021-10-06T08:30:02

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.